Yu Ruohan, Zhang Lina, Zhang Jing, Long Ting, Li Ji, Zou Yadan, Wang Shangxi, Li Shengguang
Department of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Health Management Center, Peking University International Hospital, Beijing, China.
Front Immunol. 2025 Jun 17;16:1588287. doi: 10.3389/fimmu.2025.1588287. eCollection 2025.
ANCA-associated vasculitis (AAV) is a group of autoimmune diseases characterized by small vessel inflammation, diagnosed primarily through clinical features, histopathology, and ANCA testing. Novel biomarkers derived from routine blood counts, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), may support disease assessment. This study evaluated their utility in distinguishing AAV patients, reflecting disease activity, and predicting prognosis.
In this retrospective case-control study, 65 AAV patients and 65 age- and sex-matched healthy controls were enrolled. AAV diagnosis adhered to the 2012 Chapel Hill Consensus and the American College of Rheumatology 1990 criteria. NLR, PLR, MLR, SII, and SIRI were calculated from complete blood counts. Disease activity (Birmingham Vasculitis Activity Score, BVAS), extent (Disease Extent Index, DEI), damage (Vasculitis Damage Index, VDI), and prognosis (Five-Factor Score, FFS 2009) were assessed. Statistical analyses included Mann-Whitney U tests, Spearman correlations, and receiver operating characteristic (ROC) curves to evaluate discriminatory and predictive capacities.
AAV patients exhibited significantly higher NLR (6.94 ± 0.76 vs. 1.88 ± 0.08), PLR (242.44 ± 23.09 vs. 125.97 ± 4.34), MLR (0.44 ± 0.03 vs. 0.20 ± 0.01), SII (1813.71 ± 221.85 vs. 446.62 ± 22.40), and SIRI (3.19 ± 0.31 vs. 0.72 ± 0.06) compared to controls (all P < 0.001). ROC analysis showed strong discriminatory power, with SIRI (AUC = 0.902) and NLR (AUC = 0.885) performing best. NLR, PLR, SII, and SIRI correlated positively with BVAS (rs = 0.325-0.356, < 0.01) and FFS 2009 (rs = 0.358-0.386, < 0.05), and all markers correlated with DEI (rs = 0.396-0.488, < 0.01), but not VDI. For predicting active disease (BVAS ≥ 15), SII had the highest AUC (0.726, = 0.003).
NLR, PLR, MLR, SII, and SIRI effectively distinguish AAV patients from controls and reflect disease activity, extent, and prognosis. While not standalone diagnostic tools, these markers offer valuable support to standard AAV assessment, particularly in challenging cases. Their accessibility suggests potential for enhancing clinical management, pending validation in larger cohorts.
抗中性粒细胞胞浆抗体相关性血管炎(AAV)是一组以小血管炎症为特征的自身免疫性疾病,主要通过临床特征、组织病理学和抗中性粒细胞胞浆抗体检测进行诊断。源自常规血常规的新型生物标志物,如中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、单核细胞与淋巴细胞比值(MLR)、全身免疫炎症指数(SII)和全身炎症反应指数(SIRI),可能有助于疾病评估。本研究评估了它们在鉴别AAV患者、反映疾病活动度和预测预后方面的效用。
在这项回顾性病例对照研究中,纳入了65例AAV患者和65例年龄及性别匹配的健康对照。AAV诊断遵循2012年《 Chapel Hill共识》和美国风湿病学会1990年标准。根据血常规计算NLR、PLR、MLR、SII和SIRI。评估疾病活动度(伯明翰血管炎活动评分,BVAS)、范围(疾病范围指数,DEI)、损伤(血管炎损伤指数,VDI)和预后(五因素评分,2009年FFS)。统计分析包括曼-惠特尼U检验、斯皮尔曼相关性分析和受试者工作特征(ROC)曲线,以评估鉴别和预测能力。
与对照组相比,AAV患者的NLR(6.94±0.76 vs. 1.88±0.08)、PLR(242.44±23.09 vs. 125.97±4.34)、MLR(0.44±0.03 vs. 0.20±0.01)、SII(1813.71±221.85 vs. 446.62±22.40)和SIRI(3.19±0.31 vs. 0.72±0.06)显著更高(所有P<0.001)。ROC分析显示具有较强的鉴别能力,其中SIRI(AUC = 0.902)和NLR(AUC = 0.885)表现最佳。NLR、PLR、SII和SIRI与BVAS呈正相关(rs = 0.325 - 0.356,P<0.01)和2009年FFS呈正相关(rs = 0.358 - 0.386,P<0.05),所有标志物均与DEI相关(rs = 0.396 - 0.488,P<0.01),但与VDI无关。对于预测活动性疾病(BVAS≥15),SII的AUC最高(0.726,P = 0.003)。
NLR、PLR、MLR、SII和SIRI能有效区分AAV患者与对照组,并反映疾病活动度、范围和预后。虽然这些标志物不是独立的诊断工具,但它们为AAV的标准评估提供了有价值的支持,特别是在具有挑战性的病例中。它们易于获取,提示在更大队列中进行验证之前,在加强临床管理方面具有潜力。